FACULTY
Understanding, Preventing, And Managing COPD
Paper Symposium
Activity Date: December 2004  — Activity Info: Volume 4, (10A)
Goals & Objectives | Faculty | Introduction | Full Activity Content | CME Test & Evaluation (CME Expired) | Order Copy of Activity

 

Full Disclosure Policy Affecting CME Activities:
As sponsors accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American Nurses' Credentialing Center (ANCC), and the Accreditation Council for Pharmacy Education (ACPE), it is the policy of Johns Hopkins University School of Medicine, The Institute for Johns Hopkins Nursing, and the University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Program Director and Participating Faculty reported the following:

PROGRAM DIRECTOR

Robert A. Wise, MD
Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Asthma and Allergy Center
Johns Hopkins University
School of Medicine
Baltimore, Maryland
• Dr Wise reports receiving grants/research support from Boehringer Ingelheim, GlaxoSmithKline, Otsuka America Pharmaceutical Inc, and Pfizer Inc; and serving as a consultant to AstraZeneca LP, Aventis, Emphasys Medical, Inc, GlaxoSmithKline, Pfizer Inc, and Spiration, Inc.

PARTICIPATING FACULTY

Michael F. Busk, MD, MPH
Associate Professor of Medicine
Division of Pulmonary, Critical Care and Occupational Medicine
Indiana University School of Medicine
Indianapolis, Indiana
• Dr Busk reports receiving honoraria from GlaxoSmithKline.

Tina V. Hartert, MD, MPH
Assistant Professor of Medicine
Vanderbilt University Center for Lung Research
Pulmonary and Critical Care Medicine
Vanderbilt University
Nashville, Tennessee
• Dr Hartert reports having no significant financial or advisory relationships with corporate organizations related to this activity.

Barry J. Make, MD
Professor of Medicine
Director, Emphysema Program, Pulmonary Rehabilitation, and Respiratory Care
National Jewish Medical and Research Center
University of Colorado
Denver, Colorado
• Dr Make reports receiving grants/research support from Boehringer Ingelheim, GlaxoSmithKline, F. Hoffman-LaRoche Ltd, and Pfizer Inc; serving as a consultant and is a member of the speakers' bureau for Bayer Pharmaceuticals Corporation, Boehringer Ingelheim, GlaxoSmithKline, and Pfizer Inc.

John J. Reilly, MD
Associate Professor of Medicine
Medical Director, Pulmonary Rehabilitation Program
Clinical Director, Pulmonary and Critical Care Medicine
Brigham and Women's Hospital
Harvard Medical School
Boston, Massachusetts
• Dr Reilly reports receiving honoraria from and is a member of the speakers' bureau for Boehringer Ingelheim and GlaxoSmithKline.

Paul D. Scanlon, MD
Professor of Medicine
Mayo Clinic
Rochester, Minnesota
• Dr Scanlon reports receiving grants/research support from Boehringer Ingelheim and GlaxoSmithKline.

Frank C. Sciurba, MD, FCCP
Associate Professor of Medicine
Director, Emphysema Research Center
Division of Pulmonary, andCritical Care Medicine
University of Pittsburgh
School of Medicine
Pittsburgh, Pennsylvania
• Dr Sciurba reports receiving grants/research support from AstraZeneca LP, Boehringer Ingelheim, Emphasys Medical, Inc, F. Hoffman-LaRoche Ltd, GlaxoSmithKline, Otsuka America Pharmaceutical, Inc, and Sepracor Inc; and serving as a consultant to Amgen Inc, F. Hoffman-LaRoche Ltd, GlaxoSmithKline, and Pfizer Inc.

Notice: In accordance with the ACCME Standards for Commercial Support, the audience is advised that one or more articles in this continuing medical education activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices. The following faculty members have disclosed that they have referenced the following unlabeled/unapproved uses of drugs or devices:

Dr Busk—bronchodilators, inhaled corticosteroids.

Dr Make—albuterol, albuterol/ipratropium, beclomethasone, bronchodilators, budesonide, formoterol, formoterol/budesonide, ipratropium, methylprednisone, prednisone, salmeterol, salmeterol/fluticasone, theophylline, tiotropium, triamcinolone.

All other faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs or devices.

Advanced Studies in Medicine provides disclosure information from contributing authors, lead presenters, and participating faculty. Advanced Studies in Medicine does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.

     
Home | Contact Us | View Account | Need Help?